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Materials and Methods: Candidates for the study were recurrence-
free patients treated with primary radiotherapy (IMRT) for oral, 
pharyngeal and laryngeal cancer from 2006 to 2011 and attending 
follow-up between January1st and May 7th 2012. A total of 65 patients 
(44%) accepted the invitation to participate in a follow-up study 
including Modified Barium Swallow (MBS), EORTC QLQ C30 and H&N35, 
mouth opening, Charlsons co-morbidity index and smoking status. 
Data on patient, tumor and treatment characteristics were obtained 
from the DAHANCA database: Larynx 37%, pharynx 52%, oral cavity 
11%; median age 63 years, 85% men, 57% stage IV disease; weekly 
cisplatin 41%, Zalutumumab 16%. DVHs of the following OARs were 
analyzed: pharyngeal constrictor muscles (sup, mid. and inf. PCM), 
cricopharyngeal muscle, esophagus inlet muscle (EIM), cervical 
esophagus (CE), base of tongue, glottic and supraglottic larynx. Data 
were analyzed with dichotomized endpoints and logistic regression 
models. 
Results: Median follow-up after treatment was 3.3 years (range 1.0 - 
5.3).There was no significant difference between participants and 
non-participants regarding patient, tumor and treatment 
characteristics, as well as maximum DAHANCA score for early and late 
dysphagia. The most frequent objective swallowing dysfunction was 
retention on MBS, occurring in 41 of the 65 patients (63%)[Table 1]. 
Penetration and aspiration was less common, 31% and 6%, 
respectively. The QoL data showed low degree of dysphagia with 
mean scores of 11-13, respectively. In general the different endpoints 
did not correlate well with each other indicating that they describe 
different aspects of swallowing morbidity. This difference was 
reflected in the correlations between swallowing endpoints and dose 
to the OAR. In general, complications observed on MBS and observer 
assessed late dysphagia correlated with the dose to superior and 
middle PCM (all p-values below 0.04), whereas quality of life 
endpoints correlated with dose-volume parameters in the larynx and 
supraglottic larynx (p values below 0.05).  
 
  
Conclusions: In this cohort of patients treated with IMRT, a high rate 
of retention was found on MBS whereas most other dysphagia-related 
endpoints occurred with a lower frequency. Significant relationships 
between dysphagia measures and dose-volume characteristics were 
found for specific OARs, especially the superior and middle PCM. 
Dysphagia is not sufficiently described using a single endpoint. 
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Purpose/Objective: To determine the impact of intensity-modulated 
radiotherapy (IMRT) in developing post-treatment hypothyroidism in 
nasopharyngeal carcinoma (NPC) patients, and to investigate the 
possible factors that could predict the onset of hypothyroidism. 
Materials and Methods: We retrospectively collected thyroid function 
of patient received radiotherapy for nasopharyngeal carcinoma at our 
hospital. Between January 2000 to December 2008, 191 patients were 
included into our study. There were 142 males and 49 females, with 
the median age of 48 years old. Table 1 summarized the 
characterisitcs of patients and treatment. Thyroid function was 
evaluated by measuring thyroid stimulating hormone (TSH) and serum 
free thyroxine(FT4). Elevated TSH level is documented as subclinical 
hypothyroidism and low level of FT4 is classified as clinical 
hypothyroidism. The risk factors analyzed in this study included age, 
gender, pathology, tumor and nodal extent, treatment modality, re-
irradiation, and chemotherapy. 
 
  
Results: With a median follow-up of 5.24 years (range, 0.18-12.2 
years), the incidence rates of clinical hypothyroidism in entire 
patients were 9.9%, 21.8 % and 43.3%, respectively in 3 years, 5 years, 
and 10 years follow up. In univariate analysis, subclinical 
hypothyroidism was more common in younger age (<30 years vs. 30 
years; P=0.022), advanced N stage (N3b vs. N0-3a; P=0.005), and IMRT 
group (IMRT vs. conventional radiotherapy; P<0.001). (Figure 1) While 
advanced T stage (T3-4 vs. T1-2; P<0.001), advanced N stage (N3b vs. 
N0-3a; P=0.045), and IMRT (IMRT vs. conventional radiotherapy; 
P<0.001) were significant factors that determine clinical 
hypothyroidism. IMRT group remained significant in developing both 
clinical (P<0.001) and subclinical (P<0.001) hypothyroidism in 
multivariate analysis while compared to traditional radiotherapy 
technique. The incidence rates of clinical hypothyroidism in IMRT 
group were 14.7 %, 42.3 % and 61.5 %, respectively in 3 years, 5 years, 
and 8 years follow up. 
 
  
Conclusions: More than half of NPC patients will experience clinical 
hypothyroidism after the treatment of IMRT. To avoid irreversibe 
damage, it is mandatory to set the proper dose constrain for thyroid 
organ in the future IMRT plan. 
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Purpose/Objective: Normal tissue biology may change during 
radiotherapy affecting function of organs at risk. The purpose of the 
study was to evaluate the changes of volume and proliferation level of 
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thyroid gland, parotids and bone marrow according to and FLT ((18)F-
fluoro-thymidine)-PET images, before and during the treatment.  
Materials and Methods: Patients with advanced, inoperable 
oropharynx and oral cavity cancer were treated with chemoradiation. 
(RTCT). The dose of 70 Gy in 35 fractions was delivered concurrently 
with three courses of cisplatin(100mg/m2) provided on the 1st, 22nd 
and 43rd day of treatment. FLT PET/CT was performed a week before 
and then on 7th and 14th day of treatment, corresponding to a dose of 
14 and 28 Gy respectively. The whole imaging was performed while 
ensuring the same mode of patient’s immobilization i.e. individual 
thermoplastic mask. Volumes of thyroid gland, both parotids and 
cervical vertebrae were measured on CT scans obtained before 
treatment and at the FLT PET time point. CT and PET images were 
matched to assess the level of proliferation at the organ of interest. 
SUV mean was used to quantify differences in proliferation level. 
Thyroid hormones level were assayed prior to the treatment and then, 
weekly during the treatment followed by the one month after 
completion of the treatment evaluation to assess the level of 
functional changes. For statistical calculation Pearson’s correlation 
coefficient and Wilcoxon Matched Pair Test were used, for alpha=0.5  
Results: Both volume and FLT SUVmean of the thyroid gland 
decreased during treatment (p= 0.009 and 0.03 respectively). Changes 
of volume of thyroid gland correlated with the decrease of FLT 
SUVmean in the first week of treatment. (R=0.90) Thyroid hormones 
levels fluctuate during and after chemoradiation. Thyroid-stimulating 
hormone (TSH) level measured a month after RTCT negatively 
correlates with FLT SUVmean in the first week of treatment (R=0.89) 
Volume of homolateral and contralateral parotids decreases 
significantly during first week of treatment (p=0.003 and 0.01 
respectively). Degree of parotid volume change depends on its initial 
volume before treatment (R=0.7). FLT SUVmean reduction in bone 
marrow after first week of treatment reflects depletion of 
proliferating cells (p=0.002) 
Conclusions: Morphologica land functional changes in head and neck 
organs can be estimate during RTCT. Assessment of the volumetric 
and metabolic changes of certain organ at risk during treatment could 
be a predictor of their future function and can help in further 
individualization of treatment planning.  
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Purpose/Objective: Besides basic measurements as SUVmax, SUVmean or 
tumor volume derived from 18F-FDG PET scans, more advanced 
quantitative imaging features are increasingly investigated for 
treatment monitoring and outcome prediction. This is within the 
context of Radiomics: extracting and mining a large number of 
quantitative features from medical images, where it is hypothesized 
that it will improve tumor characterization and outcome prediction. 
However, in order to use these features for future prognostic and 
predictive models, it is required that they are reliable. This study 
therefore aims to assess the repeatability of Radiomics features 
derived from PET images in NSCLC. 
Materials and Methods: Eleven NSCLC patients were included 
retrospectively in this study. All patients underwent two baseline 18F-
FDG PET scans within a one day interval, before any treatment was 
delivered. 60-min. emission scans were obtained on an ECAT EXACT 
HR+ scanner (Siemens/CTI) in 2D mode and reconstructed using 
OSEM2Dx16s, followed by 5mm FWHM Gaussian post-smoothing. Per 
patient, all lesions with adequate uptake and contrast were identified 
and delineated by applying one of four predefined thresholds of the 
maximum uptake value within the tumor (41%, 50% and 70% corrected 
for local background and 50% uncorrected for background) (figure 1). 
The extracted image features comprised 15 first-order statistics, 33 
textural features derived from gray level co-occurrence and gray level 
run-length matrices, 51 metabolic descriptors of the intensity volume 
histogram (IVH) and 7 features describing the shape and size of the 
delineated VOI. Repeatability for every extracted image feature was 
assessed with the intraclass correlation (ICC) and the coefficient of 
repeatability (COR), expressed as a percentage of the sample 
estimated reference range. 
 
 
Results: 32 lesions were selected for analysis. Repeatability analysis 
of shape and size characteristics of the defined VOIs revealed a good 
agreement between the two baseline scans, with ICC and COR values 
ranging from 0.94-1 and 2.8%-17.1% respectively for all 7 features. 
13/15 of the considered first order statistics showed high repeatability 
with an ICC between 0.77–0.96 and a COR between 12.3%-38.6%. An 
ICC between 0.7-1 and a COR of 3.6%-37.2% was found for 28/33 
textural features. From the IVH features, 40/51 were highly 
repeatable with an ICC and a COR of 0.78-1 and 2.8%-31.4% 
respectively. The overall results are summarized in table 1. 
 
  
Conclusions: The results of this study indicate that the majority of 
assessed PET image features are highly repeatable and suggest that 
further analysis of these parameters may be warranted for treatment 
monitoring and outcome prediction in NSCLC. 
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Purpose/Objective: To test the hypothesis that cardiac comorbidity 
before the start of (chemo)radiotherapy (RCHT) is associated with an 
increased risk of radiation induced lung toxicity (RILT) in lung cancer 
patients. 
Materials and Methods: A prospective cohort of 149 non-resectable 
lung cancer patients with locoregional disease was studied, that was 
treated with definite (chemo)radiotherapy between 2007 and 2011 
(ClinicalTrials.gov Identifiers: NCT00572325 and NCT00573040). Prior 
to oncological therapy, 42 (28.2%) patients had recorded treatment of 
cardiovascular pathologies at a cardiology department and 44 (29.5%) 
developed RILT, measured by dyspnea grade ≥ 2 according to CTCv.3.0 
within 6 months after radiotherapy. 
Results: Half of the patients with cardiac comorbidity (21/42) 
presented with dyspnea grade ≥ 2 within 6 months after RCHT, 
compared to 21.5% (23/107) of those without such comorbidity. The 
odds ratio of RILT for a patient with a cardiac comorbidity was 3.65 
(p-value < 0.001, 95% CI: 1.70 – 7.81, see Figure 1). Conversely, for 
common factors associated with RILT, such as mean lung dose, age, 
smoking status, World Health Organization performance status and 
Forced Expiratory Volume in 1 second no significant associations were 
